Literature DB >> 1255667

Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6.

D H Coy, J A Vilchez-Martinez, E J Coy, A V Schally.   

Abstract

The incorporation of simple d-amino acids in place of glycine in position 6 of the LH-RH decapeptide produces analogs which have far greater gonadotropin-releasing activities in vivo and in vitro than the natural hormone. An investigation of the structural features of the d-amino acids responsible for this phenomenon suggests that an increase in the lipophilic character and perhaps the size and aromaticity of the side chain coincides with an increase in biological activity. This is demonstrated by the LH-releasing activities of the following series of peptides which were assayed over a period of 6 h in immature male rats: [d-Glu(6)]-,1.8;[d-Ala(6)]-,7.0;[d-Leu(6)]-,9,0;[d-Phe(6)]-,10;[d-Trp(6)]-LH-RH, 13 times more active than LH-RH itself. In contrast to previous results with [d-Ala(6)]-and [d-Leu(6)]-LH-RH, where the substitution of an ethylamide group for the glycine amide at the C-terminus produces large increases in LH/FSH releasing activity, the ethylamide derivatives of [d-Phe(6)]-and [d-Trp(6)]-LH-RH were actually less potent than their parent peptides. [(N-Me-d-Ala)(6)]-LH-RH was found to be approximately 70 times less active than [d-Ala(6)]-LH-RH which indicates that disruption of a preferred receptor-site binding conformation might be brought about by methylation of the amide linkage in this position.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1255667     DOI: 10.1021/jm00225a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

1.  Low energy conformations for gonadotropin-releasing hormone with D- and L-amino acid substitutions for Gly 6: possible receptor-bound conformations.

Authors:  Matthew R Pincus; Jannie Woo; Regina Monaco; Jack Lubowsky; Robert P Carty
Journal:  Protein J       Date:  2014-12       Impact factor: 2.371

Review 2.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

3.  Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.

Authors:  Zoltan Rekasi; Tamas Czompoly; Andrew V Schally; Ferenc Boldizsar; Jozsef L Varga; Marta Zarandi; Timea Berki; Reka A Horvath; Peter Nemeth
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

4.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Authors:  G Tolis; D Ackman; A Stellos; A Mehta; F Labrie; A T Fazekas; A M Comaru-Schally; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

5.  Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study.

Authors:  J R Mathias; M H Clench; V G Reeves-Darby; L M Fox; P H Hsu; P H Roberts; L L Smith; N J Stiglich
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

6.  Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.

Authors:  Eija A Lundström; Rupert K Rencken; Johann H van Wyk; Lance J E Coetzee; Johann C M Bahlmann; Simon Reif; Erdam A Strasheim; Martin C Bigalke; Alan R Pontin; Louis Goedhals; Douw G Steyn; Chris F Heyns; Luigi A Aldera; Thomas M Mackenzie; Daniela Purcea; Pierre Y Grosgurin; Hervé C Porchet
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

7.  Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.

Authors:  T W Redding; A V Schally; T R Tice; W E Meyers
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

8.  Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.

Authors:  T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.

Authors:  A V Schally; T W Redding; A M Comaru-Schally
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

10.  Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones.

Authors:  T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.